Sandostatine® LP and Hyperinsulinism

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

April 30, 2011

Study Completion Date

June 30, 2011

Conditions
Congenital Hyperinsulinism
Interventions
DRUG

Sandostatine LP

Intramuscular injection of Sandostatine LP, once per month Dosage : 10 mg, 20 mg, 30 mg

Trial Locations (1)

75015

Necker Hospital, Paris

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Assistance Publique - Hôpitaux de Paris

OTHER